LENZ Therapeutics

LENZ · NASDAQ

$3.19−$0.11 (−3.33%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.30

Latest news

Press releaseOct 6, 6:27 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Press releaseSep 24, 5:34 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Press releaseSep 22, 6:15 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Press releaseSep 3, 10:15 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Press releaseSep 1, 5:31 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
NewsAug 11, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseAug 11, 4:05 PM ETGlobe Newswire
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
NewsJun 24, 1:41 PM ETVandana Singh
LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst
Press releaseJun 7, 7:30 PM ETGlobe Newswire
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
Press releaseMay 11, 4:05 PM ETGlobe Newswire
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
NewsMay 11, 7:11 AM ET
Earnings Scheduled For May 11, 2026
Press releaseApr 23, 9:00 AM ETGlobe Newswire
LENZ Therapeutics, Inc. Investigated by the Portnoy Law Firm
NewsApr 20, 8:04 AM ET
LENZ Therapeutics Files Marketing Authorization Application Review, Approval Of VIZZ To Medicines And Healthcare products Regulatory Agency To Treat Presbyopia In Adults
Press releaseApr 20, 8:00 AM ETGlobe Newswire
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
Press releaseMar 24, 8:00 AM ETGlobe Newswire
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
NewsMar 24, 7:11 AM ET
Earnings Scheduled For March 24, 2026
NewsMar 10, 8:08 AM ET
LENZ Therapeutics Submits Marketing Authorization Application To EMA For Review, Approval Of VIZZ To Treat Presbyopia In Adults
Press releaseMar 10, 8:00 AM ETGlobe Newswire
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
NewsJan 30, 1:02 PM ETVandana Singh
New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug
Press releaseJan 22, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Press releaseJan 15, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Press releaseJan 14, 8:30 AM ETPRNewswire
LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign
Press releaseJan 8, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Press releaseJan 1, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
NewsNov 5, 6:12 AM ET
Earnings Scheduled For November 5, 2025
Press releaseSep 30, 8:05 AM ETPRNewswire
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
NewsAug 11, 8:08 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsAug 11, 5:22 AM ETAvi Kapoor
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket
NewsAug 1, 10:25 AM ETVandana Singh
LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People
NewsMay 7, 4:33 AM ET
Earnings Scheduled For May 7, 2025
NewsMar 19, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsMar 19, 4:32 AM ET
Earnings Scheduled For March 19, 2025
NewsOct 28, 6:32 AM ETAvi Kapoor
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
NewsOct 21, 10:32 AM ETHenry Khederian
Why LENZ Therapeutics Stock Hit A New 52-Week High Today
Press releaseOct 15, 8:00 AM ETBusiness Wire
Lucy Therapeutics Appoints Kim Drapkin as Board Chair

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

12 Health Care Stocks Moving In Tuesday's After-Market Session

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Earnings Scheduled For May 11, 2026

LENZ Therapeutics, Inc. Investigated by the Portnoy Law Firm

LENZ Therapeutics Files Marketing Authorization Application Review, Approval Of VIZZ To Medicines And Healthcare products Regulatory Agency To Treat Presbyopia In Adults

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Earnings Scheduled For March 24, 2026

LENZ Therapeutics Submits Marketing Authorization Application To EMA For Review, Approval Of VIZZ To Treat Presbyopia In Adults

LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

Earnings Scheduled For November 5, 2025

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

12 Health Care Stocks Moving In Monday's Pre-Market Session

Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket

LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People

Earnings Scheduled For May 7, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session

Earnings Scheduled For March 19, 2025

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Why LENZ Therapeutics Stock Hit A New 52-Week High Today

Lucy Therapeutics Appoints Kim Drapkin as Board Chair